Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 491

1.

Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.

Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM.

J Clin Oncol. 2004 Dec 15;22(24):4951-7. Epub 2004 Dec 14.

PMID:
15598980
2.

Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.

Rondanina G, Puntoni M, Severi G, Varricchio C, Zunino A, Feroce I, Bonanni B, Decensi A.

J Clin Oncol. 2008 Mar 20;26(9):1537-43. doi: 10.1200/JCO.2007.13.6739.

PMID:
18349406
3.

Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.

Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, Nuovo J, Keyzer J, Henderson S.

Cancer. 2005 May 15;103(10):1996-2005.

4.
5.

Patient reluctance toward tamoxifen use for breast cancer primary prevention.

Port ER, Montgomery LL, Heerdt AS, Borgen PI.

Ann Surg Oncol. 2001 Aug;8(7):580-5.

PMID:
11508619
6.

Chemoprevention of breast cancer.

Thomsen A, Kolesar JM.

Am J Health Syst Pharm. 2008 Dec 1;65(23):2221-8. doi: 10.2146/ajhp070663. Review.

PMID:
19020189
7.

Acceptance of tamoxifen chemoprevention by physicians and women at risk.

McKay A, Latosinsky S, Martin W.

Cancer. 2005 Jan 1;103(1):209-10. No abstract available.

8.

Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.

Peshkin BN, Isaacs C, Finch C, Kent S, Schwartz MD.

J Clin Oncol. 2003 Dec 1;21(23):4322-8.

PMID:
14645421
9.

Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.

Goldenberg VK, Seewaldt VL, Scott V, Bean GR, Broadwater G, Fabian C, Kimler B, Zalles C, Lipkus IM.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):1032-4.

10.

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.

Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH.

J Natl Cancer Inst. 2003 Apr 2;95(7):526-32.

PMID:
12671020
11.

The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial.

Kinney AY, Richards C, Vernon SW, Vogel VG.

Prev Med. 1998 Sep-Oct;27(5 Pt 1):713-9.

PMID:
9808803
12.
13.
15.

Chemoprevention of breast cancer for women at high risk.

Chan K, Morris GJ.

Semin Oncol. 2006 Dec;33(6):642-6. Review.

PMID:
17145342
16.

Factors implicated in the decision whether or not to join the tamoxifen trial in women at high familial risk of breast cancer.

Lovegrove E, Rumsey N, Harcourt D, Cawthorn SJ.

Psychooncology. 2000 May-Jun;9(3):193-202.

PMID:
10871715
17.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

PMID:
16288118
18.

Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis.

Ozanne EM, Esserman LJ.

Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2043-52.

20.

Women's interest in chemoprevention for breast cancer.

Bastian LA, Lipkus IM, Kuchibhatla MN, Weng HH, Halabi S, Ryan PD, Skinner CS, Rimer BK.

Arch Intern Med. 2001 Jul 9;161(13):1639-44.

PMID:
11434796

Supplemental Content

Support Center